From Nasdaq: 2025-05-23 01:19:00

Genentech, a member of the Roche Group, released two-year follow-up data from the Phase III STARGLO study showing a 40% improvement in overall survival for patients treated with Columvi in combination with GemOx compared to Rituxan plus GemOx. The updated data demonstrate a statistically significant and clinically meaningful survival benefit for people with relapsed or refractory diffuse large B-cell lymphoma. After treatment with Columvi, 89% of patients with a full response were still alive, and 82% showed no signs of cancer one year post-treatment. Columvi is approved in over 30 countries and has been added to NCCN Guidelines.



Read more at Nasdaq: Genentech’s Columvi Improves Survival Rates In Two-Year Cancer Study